Drugs / QL1012
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05149924 | Oct 2018 → Oct 2019 | female infertility | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QL1012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05149924 ↗ |
| Known as | Recombinant Human Follicle-stimulating Hormone | “QL1012 (a new biosimilar formulation of Recombinant Human Follicle-stimulating Hormone)” NCT05149924 ↗ |
| Modality | Protein / enzyme biologic | “QL1012 (a new biosimilar formulation of Recombinant Human Follicle-stimulating Hormone)” NCT05149924 ↗ |
| Route | Subcutaneous | “Subcutaneous injection” NCT05149924 ↗ |